CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F07%3A00092894" target="_blank" >RIV/68378050:_____/07:00092894 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

Original language description

Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneicC57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.

Czech name

CpG oligonukleotidy jsou účinné při terapii minimální zbytkové nádorové choroby MHC I negativních myších nádorů asociovaných s HPV16 po chemoterapii nebo jejich chirurgickém dstranění

Czech description

Byla analyzována účinnost CpG oligonukleotidů obsahujících dimery guanin-cytidin inhibovat růst rekurencí MHC I negativních myších nádorů asociovaných s HPV16 po chemoterapii nebo po jejich chirugickém odstranění. Podání CpG oligonukleotidů signifikantněinhibovalo růst rekurencí nádorů a lze je proto použít pro terapii nádorů jak MHC I pozitivních, tak i jejich MHC I negativních variant vzniklých v průběhu růstu nádorů vlivem imunoselekčního prostředí.

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2007

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Oncology

ISSN

1019-6439

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

5

Country of publishing house

GR - GREECE

Number of pages

5

Pages from-to

1247-1251

UT code for WoS article

—

EID of the result in the Scopus database

—